{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-24-000096","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.849709+00:00","generated_at":"2026-05-30T01:54:18.116298+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acumen Q3 net loss $29.8M; cash $258.9M; ALTITUDE-AD enrollment on track for H1 2025","bullets":["Net loss of $29.8M for Q3 2024 vs $13.0M in Q3 2023, driven by higher R&D costs ($27.2M vs $11.2M).","Cash, equivalents and marketable securities of $258.9M as of Sept 30, 2024, expected to fund operations into H1 2027.","Phase 2 ALTITUDE-AD enrollment for sabirnetug expected to complete in first half of 2025.","Topline results from Phase 1 subcutaneous sabirnetug study anticipated in Q1 2025.","Appointed Amy Schacterle, PhD as Chief Regulatory Officer & Head of Quality in November 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-24-000096","json":"https://secwatch.observer/filing/0001576885-24-000096.json","markdown":"https://secwatch.observer/filing/0001576885-24-000096.md","text":"https://secwatch.observer/filing/0001576885-24-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/0001576885-24-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:54:18.116298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}